280110-76-1

Basic information

• Product Name: 2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride
• Synonyms: 2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride;Piperidine, 4-(5-methyl-1,3,4-oxadiazol-2-yl)-, hydrochloride (1:1);EOS-61099
• CAS NO: 280110-76-1
• Molecular Formula: C8H14ClN3O
• Molecular Weight: 203.66926
• Mol File: 280110-76-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride(280110-76-1)
• EPA Substance Registry System: 2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride(280110-76-1)

Safety Data

• Hazardous Substances Data: 280110-76-1(Hazardous Substances Data)

Usage

General Description

2-Methyl-5-(piperidin-4-yl)-1,3,4-oxadiazole hydrochloride is a chemical compound often used in research and pharmaceutical applications. It is a salt form of a heterocyclic compound that contains a piperidine ring and an oxadiazole ring. The piperidine ring is a six-membered ring containing five carbon atoms and one nitrogen atom, while the oxadiazole ring is a five-membered ring containing two carbon atoms, one nitrogen atom, and two oxygen atoms. The hydrochloride salt form makes the compound more water-soluble and enhances its bioavailability for medical use. The compound may have potential in the development of new drugs or as a research tool for studying the effects of the compound on biological systems.

Upstream product

• 280110-69-2 4-(5-methyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.